Clinical Trials Browser

Phase 2 × Breast Neoplasms × talimogene laherparepvec × Clear all

NCT02658812 2023-01-25

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Terminated

11 enrolled 16 charts

Breast Neoplasms, Inflammatory Breast Neoplasms